Search Results
Search for other papers by Marcos Daniel Bortz in
Google Scholar
PubMed
Search for other papers by Andres Rodriguez in
Google Scholar
PubMed
Search for other papers by Maria Romina Luca in
Google Scholar
PubMed
Search for other papers by Federico Waisberg in
Google Scholar
PubMed
Search for other papers by Diego Enrico in
Google Scholar
PubMed
Search for other papers by Berenice Freile in
Google Scholar
PubMed
Search for other papers by Greta Catani in
Google Scholar
PubMed
Search for other papers by Federico Esteso in
Google Scholar
PubMed
Search for other papers by Marina Musumeci in
Google Scholar
PubMed
Search for other papers by Eliana Vazquez in
Google Scholar
PubMed
Search for other papers by Matias Chacón in
Google Scholar
PubMed
Search for other papers by Juan Manuel Manuel OConnor in
Google Scholar
PubMed
Search for other papers by Silvina Racioppi in
Google Scholar
PubMed
Objectives: We aim to investigate the time toxicity of patients with gastroenteropancreatic-neuroendocrine tumours treated with lutetium-177 Dotatate in a single institution.
Design: This is a retrospective cohort study.
Methods: All patients with gastroenteropancreatic-neuroendocrine tumours treated with lutetium-177 Dotatate in the Alexander Fleming Institute were included. Our primary endpoint was to evaluate time toxicity, which accounted for every day that the patient had contact with any department of any healthcare institution.
Results: Our cohort included 21 patients with metastatic disease, female sex 86%, and had a median age of 55 (IQR 44-63). The primary tumour site was small intestine in 47.6% of the cases. The median number of previous systemic treatments for advanced disease was 2 (IQR 2 - 3). The overall response rate was 19%, and 66.6% had disease clinical benefit. The median calculated 'time toxicity' was 11 days (IQR 8-18), representing 5.7% of the total treatment duration. The main contributors to time-toxicity included infusion days, blood draws, radiological scans, and hospitalizations (median 4 days for each).
Conclusion: Lutetium-177 Dotatate treatment for gastroenteropancreatic-neuroendocrine tumours was associated with a low time toxicity, excellent tolerability, good response and a prolonged PFS, of which the median was not reached in the short follow-up we present. Newer treatments with different mechanisms of action provide longer survivals and widen the landscape of choices. Understanding new clinical endpoints is important for the transition into a more modern clinical practice, strengthening personalised and patient-oriented strategies.